Demographic | Total patients (n = 75) | Study NO21895 (RO5126766) (n = 41) | Study BO21189 (RO4987655) (n = 34) |
Male (n) | 49 (65.3) | 27 (65.9) | 22 (64.7) |
Age (y) | |||
Median | 52 | 52 | 50 |
Range | 24–79 | 24–74 | 27–79 |
Height (cm) | |||
Median | 174 | 171 | 180 |
Range | 150–196 | 150–196 | 150–192 |
Weight (kg) | |||
Median | 76 | 75 | 77 |
Range | 44–128 | 52–128 | 44–119 |
Baseline Eastern Cooperative Oncology Group performance status (n) | |||
0 | 33 (44.0) | 18 (43.9) | 15 (44.1) |
1 | 42 (56.0) | 23 (56.1) | 19 (55.9) |
Primary cancer site (n) | |||
Melanoma | 33 (44.0) | 17 (41.5) | 16 (47.1) |
Colon or rectum | 18 (24.0) | 8 (19.5) | 10 (29.4) |
Lung | 4 (5.3) | 2 (4.9) | 2 (5.9) |
Ovary | 4 (5.3) | 2 (4.9) | 2 (5.9) |
Other | 16 (21.3) | 12 (29.3) | 4 (11.8) |
Patients on both studies had received median of 3 prior anticancer therapies (BO21189: range, 1–9; NO21895: range, 1–11).
Data in parentheses are percentages.